Young Kwon and Alchemab profiled in In Vivo

Many thanks to Chloe Kent at In Vivo for her great interview with our CEO Young Kwon. In her story, titled Alchemab Is Bringing A New Meaning To Patient Centered Care, Chloe explores how the first step in our drug discovery journey starts with individual patients. As we target diseases across neurology and oncology through naturally occurring protective antibodies, we mine the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.

Young states: “Alchemab was founded on the idea that there are people who are resilient to disease, or perhaps just unusually well, and that resilience is in part due to the fact that they have an immune system which is helping to fight off different diseases.”